<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964349</url>
  </required_header>
  <id_info>
    <org_study_id>Alazhar faculty of medicine</org_study_id>
    <secondary_id>Ahmed Kadah</secondary_id>
    <secondary_id>Eman Abd-ellatif</secondary_id>
    <nct_id>NCT04964349</nct_id>
  </id_info>
  <brief_title>Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata</brief_title>
  <acronym>AA</acronym>
  <official_title>Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al-Azhar University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alopecia areata is believed to be an autoimmune disease. Treatment primarily relies on&#xD;
      intralesional and topical corticosteroids. This study was conducted to evaluate Jessener&#xD;
      Solutionas a potential therapeutic modality of Alopecia Areataversusintralesional steroid as&#xD;
      regards the efficacy, safety, tolerability, and patients' satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Alopecia areata is believed to be an autoimmune disease resulting from a breach in&#xD;
      the immune privilege of the hair follicles causing non scarring hair loss.Treatment primarily&#xD;
      relies on intralesional and topical corticosteroids.Up till now, there is nouniversally&#xD;
      proven therapy that induces and maintains remission of Alopecia Areata in all patients.&#xD;
&#xD;
      Aims The Aim of Study is to evaluate the efficacyof Jessener solution versus intralesional&#xD;
      steroid in treatment of Alopecia Areata.&#xD;
&#xD;
      Patients and Methods The study will include 40 patients diagnosed clinically and&#xD;
      dermoscopically as Alopecia Areata with more than two patches of alopecia areata were&#xD;
      included. Two treatment modalities with intralesional corticosteroid and topical Jessener&#xD;
      Solutionas were performed in two randomly selected patches. Three sessions were done, 3 weeks&#xD;
      apart and were followed-up for three months. Evaluation was done using Mac Donald Hull and&#xD;
      Norris grading system , Serial photographs and dermoscopic , trichoscopic examination every&#xD;
      month will be done and patient will be score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>there are 2 patches of alopecia areata in the same patient one treated with intralesional injection of corticosteroid and the other one will be treated by jessenersolution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effecacy of topical jessener solution in treatment of alopecia areata</measure>
    <time_frame>6 monthes</time_frame>
    <description>Effecacy of topical jessener solution in treatment of alopecia areata</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Intralesional cortisosteroid injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intralesional corticosteroid injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>jessener solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical jessener solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids Acting Locally</intervention_name>
    <description>topical application of jessener solution</description>
    <arm_group_label>Intralesional cortisosteroid injection</arm_group_label>
    <arm_group_label>jessener solution</arm_group_label>
    <other_name>topical jessener solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Alopecia Areatamultilocuolaris.2.Age from18-50years old. 3.Wash out period is two&#xD;
             months. 4.Ophiasis pattern alopecia areata.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 12 yearsand more than 40years old. 2.Patient under treatment.3.Patients&#xD;
             having another dermatological condition affecting thescalpas eczema.4.Patients with&#xD;
             psychiatric disorders.5.Pregnant and lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elshahid, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alazhar faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed pr Elshahid, MD</last_name>
    <phone>00201006262271</phone>
    <phone_ext>dermatology</phone_ext>
    <email>ahmedandro@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alazhar faculty of meidicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed Elshahid, MD</last_name>
      <phone>+201006262271</phone>
      <email>ahmedandro@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Azhar University</investigator_affiliation>
    <investigator_full_name>Ahmed Rashad Elshahid</investigator_full_name>
    <investigator_title>professor of dermatology, venereology and andrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

